Neon Bloom, Inc. (NBCO)
USD 0.01
(-7.0%)
USD 0.01
(-7.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.22 Million USD | 18.09% |
| 2022 | 1.03 Million USD | 25.51% |
| 2021 | 827.3 Thousand USD | 204.2% |
| 2020 | 271.96 Thousand USD | -64.5% |
| 2019 | 766.04 Thousand USD | 6.88% |
| 2018 | 716.75 Thousand USD | 0.0% |
| 2017 | - USD | -100.0% |
| 2016 | 64.75 Thousand USD | 0.0% |
| 2010 | 3.5 Million USD | 22.47% |
| 2009 | 2.86 Million USD | 20.5% |
| 2008 | 2.37 Million USD | -8.12% |
| 2007 | 2.58 Million USD | 5968.36% |
| 2006 | 42.57 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 2.76 Million USD | 122.98% |
| 2024 Q1 | 1.24 Million USD | 1.23% |
| 2023 Q2 | 1.05 Million USD | -1.09% |
| 2023 Q1 | 1.06 Million USD | 2.94% |
| 2023 Q4 | 1.22 Million USD | 18.21% |
| 2023 FY | 1.22 Million USD | 18.09% |
| 2023 Q3 | 1.03 Million USD | -1.88% |
| 2022 Q1 | 922.15 Thousand USD | 11.46% |
| 2022 Q4 | 1.03 Million USD | 1.84% |
| 2022 FY | 1.03 Million USD | 25.51% |
| 2022 Q3 | 1.01 Million USD | 0.0% |
| 2021 FY | 827.3 Thousand USD | 204.2% |
| 2021 Q1 | 532.08 Thousand USD | 0.0% |
| 2021 Q3 | 724.32 Thousand USD | 10.82% |
| 2021 Q4 | 827.3 Thousand USD | 14.22% |
| 2021 Q2 | 653.58 Thousand USD | 22.84% |
| 2020 Q4 | - USD | 0.0% |
| 2020 FY | 271.96 Thousand USD | -64.5% |
| 2019 FY | 766.04 Thousand USD | 6.88% |
| 2018 FY | 716.75 Thousand USD | 0.0% |
| 2017 FY | - USD | -100.0% |
| 2017 Q4 | 75.65 USD | 0.0% |
| 2017 Q3 | 75.65 USD | 0.0% |
| 2016 Q3 | 0.49 USD | 0.0% |
| 2016 FY | 64.75 Thousand USD | 0.0% |
| 2016 Q4 | 0.49 USD | 0.0% |
| 2011 Q1 | 3.13 Million USD | -10.57% |
| 2010 Q2 | 3.29 Million USD | 7.46% |
| 2010 Q4 | 3.5 Million USD | 4.14% |
| 2010 Q3 | 3.36 Million USD | 2.06% |
| 2010 Q1 | 3.06 Million USD | 7.23% |
| 2010 FY | 3.5 Million USD | 22.47% |
| 2009 Q2 | 2.43 Million USD | -3.71% |
| 2009 Q3 | 2.29 Million USD | -5.61% |
| 2009 FY | 2.86 Million USD | 20.5% |
| 2009 Q4 | 2.86 Million USD | 24.42% |
| 2009 Q1 | 2.52 Million USD | 6.57% |
| 2008 Q3 | 2.1 Million USD | -0.95% |
| 2008 Q4 | 2.37 Million USD | 12.73% |
| 2008 Q1 | 2.04 Million USD | -20.82% |
| 2008 Q2 | 2.12 Million USD | 3.91% |
| 2008 FY | 2.37 Million USD | -8.12% |
| 2007 Q3 | 2.55 Million USD | 3.97% |
| 2007 Q1 | 2.35 Million USD | 0.0% |
| 2007 Q4 | 2.58 Million USD | 1.15% |
| 2007 FY | 2.58 Million USD | 5968.36% |
| 2007 Q2 | 2.45 Million USD | 4.37% |
| 2006 FY | 42.57 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -4369.847% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 87.046% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 98.308% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -51.61% |
| Rebus Holdings, Inc. | 5.24 Million USD | 76.608% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 97.922% |
| Qrons Inc. | 1.48 Million USD | 17.633% |
| Adynxx, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 98.363% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -2643.451% |
| Skye Bioscience, Inc. | 14.07 Million USD | 91.286% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 97.7% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 87.203% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -190.87% |
| SQZ Biotechnologies Company | 50.03 Million USD | 97.549% |
| Intellipharmaceutics International Inc. | 12 Million USD | 89.789% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 68.162% |
| Mesoblast Limited | 188.44 Million USD | 99.349% |
| Marizyme, Inc. | 26.67 Million USD | 95.403% |
| Genus plc | 485 Million USD | 99.747% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 79.013% |
| Pharming Group N.V. | 244.07 Million USD | 99.498% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 38.998% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 51.27% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 67.731% |
| ContraFect Corporation | 32.53 Million USD | 96.231% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 38.111% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 67.964% |
| IMV Inc. | 37.93 Million USD | 96.767% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 89.589% |
| MultiCell Technologies, Inc. | 1617.67 USD | -75701.183% |
| ONE Bio Corp. | 27.49 Million USD | 95.54% |
| Accustem Sciences Inc. | 1.07 Million USD | -13.618% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 98.416% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 42.025% |
| Q BioMed Inc. | 8.13 Million USD | 84.923% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 98.521% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 76.172% |
| Biomind Labs Inc. | 1.49 Million USD | 18.177% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 98.967% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 86.439% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 93.337% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 14.482% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -762.953% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -509.704% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 78.659% |
| GB Sciences, Inc. | 5.41 Million USD | 77.366% |
| Alpha Cognition Inc. | 7.16 Million USD | 82.886% |
| HST Global, Inc. | 593.59 Thousand USD | -106.575% |
| CSL Limited | 18.62 Billion USD | 99.993% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 2.619% |
| Halberd Corporation | 728.71 Thousand USD | -68.27% |
| Enzolytics Inc. | 365.26 Million USD | 99.664% |
| Agentix Corp. | 2.51 Million USD | 51.158% |
| Resverlogix Corp. | 67.39 Million USD | 98.181% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -46.198% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.724% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 28.459% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 95.045% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 89.698% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 66.544% |
| AVAX Technologies, Inc. | 3.99 Million USD | 69.297% |
| Zenith Capital Corp. | 27.56 Thousand USD | -4347.796% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.908% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -413.804% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 67.164% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -80.105% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 54.78% |
| Kadimastem Ltd | 3.5 Million USD | 65.014% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -1732.11% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 97.56% |
| BioStem Technologies, Inc. | 15.9 Million USD | 92.29% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -163.873% |
| LadRx Corporation | 2.2 Million USD | 44.276% |
| Cell Source, Inc. | 15.8 Million USD | 92.242% |
| Regen BioPharma, Inc. | 5.45 Million USD | 77.532% |
| Regen BioPharma, Inc. | 5.45 Million USD | 77.532% |
| NovAccess Global Inc. | 7.86 Million USD | 84.401% |
| Affymax, Inc. | 8.87 Million USD | 86.177% |
| Itoco Inc. | 1.65 Million USD | 25.826% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 40.23% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 79.729% |
| Mobile Lads Corp. | 1.31 Million USD | 6.645% |
| CytoDyn Inc. | 127.89 Million USD | 99.041% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -2833.594% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 21.717% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 88.898% |
| SYBLEU INC | 681.41 Thousand USD | -79.952% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 79.904% |
| International Stem Cell Corporation | 5.27 Million USD | 76.763% |
| Bioxytran, Inc. | 3.24 Million USD | 62.265% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -95.94% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 73.442% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 97.009% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 94.493% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 39.458% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 77.616% |
| Neutra Corp. | 973.52 Thousand USD | -25.955% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 95.774% |
| PureTech Health plc | 125.58 Million USD | 99.024% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 67.363% |
| IXICO plc | 1.9 Million USD | 35.472% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 94.027% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.813% |
| CSL Limited | 18.62 Billion USD | 99.993% |
| Cellectis S.A. | 249.36 Million USD | 99.508% |